We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Activator Revealed Responsible for Brain Cell Damage in Huntington's Disease

By LabMedica International staff writers
Posted on 29 Jun 2009
Neuroscientists have discovered why a defective protein accumulates in cells everywhere in the bodies of individuals with Huntington's disease (HD), but only kills cells in the area of the brain that controls movement, causing insignificant damage to tissues elsewhere. More...
The answer lies in one tiny protein called Rhes that is found only in the part of the brain that controls movement. The findings help explain the distinctive pattern of brain damage in HD and its symptoms, as well as offer a new approach for new therapy.

HD itself is caused by a genetic defect that produces a mutant version of the protein huntingtin, which collects in all cells of the body, but only appears to affect the brain. Passed from parent to child through an alteration of a normal gene, HD over time causes irreversible uncontrolled movement, loss of intellectual function, emotional disturbances, and death.

"It's always been a mystery why, if the protein made by the HD gene is seen in all cells of the body, only the brain, and only a particular part of the brain, the corpus striatum, deteriorates,” said Solomon H. Snyder, M.D., a professor of neuroscience at Johns Hopkins University (Baltimore, MD, USA). "By finding the basic culprit, the potential is there to develop drugs that target it and either prevent symptoms or slow them down.”

Curious about the huntingtin protein's striatal-specific effect, Dr. Snyder's research team, led by Srinivasa Subramaniam, Ph.D., a postdoctoral fellow, looked for proteins that interacted locally, specifically, and only with huntingtin in the corpus striatum, guessing that the molecular answer to the mystery most likely would be found there.

The protein Rhes caught the investigators attention because they already were studying a related protein for other reasons. Rhes was known to be found almost exclusively in the corpus striatum. Conducting tests using human and mouse cells, they found that Rhes interacted with both healthy and mutant versions of huntingtin protein, but bound much more strongly to mutant huntingtin (mHtt). "Touching or binding is one matter, but death is altogether another,” said Dr. Snyder, so the next step was to see whether and how Rhes plus mHtt could kill brain cells in the corpus striatum.

Utilizing human embryonic cells and brain cells gathered from mice the researchers added different combinations of normal and mutant huntingtin and Rhes, and examined the cells over the next week to see if any cells died. While each protein alone did not alter the number of cells in the dishes, when both mHtt and Rhes were present in the same cells, half the cells died within 48 hours. "Here's the Rhes protein, we've known about it for years, nobody ever really knew what it did in the brain or anywhere else,” said Dr. Snyder. "And it turns out, it looks like the key to Huntington's disease.”

The researchers then went on to confront another mystery surrounding the disease, the solution to this one adding further evidence for the role Rhes plays in HD. "We've known for a long time that abnormal huntingtin proteins aggregate and form clumps in all cells of the body, but the corpus striatum of HD patients seems to have fewer of these clumps than other brain regions or the rest of the body,” said Dr. Subramaniam in describing the mystery. "This has led to much controversy: are the clumps toxic, or is it the lack of clumps that's toxic to these brain cells?”

In the study, adding Rhes to cells with abnormal huntingtin led to fewer clumps, but the cells died. The results, according to Dr. Subramaniam, suggest that Rhes might be responsible for unclumping mutant huntingtin protein and this somehow kills cells. "Since Rhes is highly found in the corpus striatum, clumping somehow protects cells in other tissues of the body from dying,” he noted.

The researchers are now exploring whether removing Rhes from mice with Huntington's disease can suppress or stop brain cells from dying. "Now that we've uncovered the role of Rhes, it's possible that drugs can be designed that specifically target Rhes to treat or even prevent the disease,” stated Dr. Snyder.

The study was funded by a U.S. Public Health Service grant and Research Scientist Awards, and the findings were published in the June 5, 2009, issue of Science.

Related Links:

Johns Hopkins University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.